Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020)

References

• Burrell CJ, Howard CR, and Murphy FA. Vaccines and vaccination. Fenner and Whiteʻs medical virology. Fifth ed. London: Academic Press; 2017. pp. 155–8.
   Google Scholar
• Wang J, Jing R, Lai X, Zhang H, Yun L, Knoll MD, Fang H. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines. 2020;8(3):482. doi:10.3390/vaccines8030482.
   PubMed Web of Science ®Google Scholar
• Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22:300–09. doi:10.1016/j.pedhc.2007.09.004.
   PubMed Web of Science ®Google Scholar
• Pan A, Organization WH. Expanded program on immunization. Int J Epidemiol. 1979;19:219–20.
   Google Scholar
• Commission NH . Procedures and instructions for childrenʻs immunization with vaccines in the National Immunization Program (2021 edition). Chin J Viral Dis. 2021;11(4):241–245 .
   Google Scholar
• Vaudaux B. Combined vaccines and vaccine combinations. Rev Med Suisse Romande. 1998;118:377–93.
   PubMedGoogle Scholar
• Peter G. Lessons learned from a review of the development of selected vaccines. Pediatrics. 1999;104(4):942–50. doi:10.1542/peds.104.4.942.
   PubMed Web of Science ®Google Scholar
• Hutchins SS, Escolan J, Markowitz LE, Hawkins C, Orenstein WA, Morgan RA, Preblud SR, Orenstein WA. Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. Pediatrics. 1989;83(3):369–74. doi:10.1542/peds.83.3.369.
   PubMed Web of Science ®Google Scholar
• King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J. 1994;13(5):394–407. doi:10.1097/00006454-199405000-00012.
   PubMed Web of Science ®Google Scholar
• WPRO. WPRO | New poliovirus vaccine licensed in China. WPRO | WHO Western Pacific Region.
   Google Scholar
• Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WAM. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine. 2014;32(39):4938–44. doi:10.1016/j.vaccine.2014.07.029.
   PubMed Web of Science ®Google Scholar
• He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis. 2020;20:1071–79. doi:10.1016/S1473-3099(19)30738-8.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet (London, England). 2015;386(10011):2413–21. doi:10.1016/S0140-6736(15)00237-8.
   PubMed Web of Science ®Google Scholar
• Li Z, Ding W, Guo Q, Ze L, Zhu Z, Song S, Li W, and Liao G. Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV). Hum Vaccin Immunother . 2018;14(8):1.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237–43. doi:10.1093/infdis/jir723.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain–based inactivated poliovirus vaccine. J Infect Dis. 2016;214:1728–34. doi:10.1093/infdis/jiw433.
   PubMed Web of Science ®Google Scholar
• Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018;36:6782–89. doi:10.1016/j.vaccine.2018.09.023.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, et al. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis. 2020. doi:10.1093/infdis/jiaa770.
   Google Scholar
• Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, et al. Immunogenicity and safety of a Sabin strain–based inactivated Polio vaccine: a phase 3 clinical trial. J Infect Dis. 2019;220(10):1551–57. doi:10.1093/infdis/jiy736.
   PubMed Web of Science ®Google Scholar
• Guo B, Page A, Wang H, Taylor R, Mcintyre P. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China. Vaccine. 2013;31:603–17. doi:10.1016/j.vaccine.2012.11.051.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33(32):4041–46. doi:10.1016/j.vaccine.2015.04.060.
   PubMed Web of Science ®Google Scholar
• Health CMo. National guideline for the Surveillance of adverse events following immunization. Chin J Vaccin Immun 2011;017:72–81.
   Google Scholar
• Wu W, Liu D, Nuorti JP, Li K, Xu D, Ye J, Zheng J, Cao L, Wang H. Deaths reported to national surveillance for adverse events following immunization in China, 2010–2015. Vaccine. 2019;37(9):1182–87. doi:10.1016/j.vaccine.2019.01.009.
   PubMed Web of Science ®Google Scholar
• Kang G, Tang F, Wang Z, Hu R, Yu J, and Gao J. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China. Hum Vaccin Immunother . 2021;17(8):2568–2574.
   PubMed Web of Science ®Google Scholar
• Jiang R, Liu X, Sun X, Wang J, and Sun M. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine . 2021;39(9):1463–1471.
   PubMed Web of Science ®Google Scholar
• White C, Halperin SA, Scheifele DW. Pediatric combined formulation DTaP–ipv/hib vaccine. Expert Rev Vaccines. 2009;8:831–40. doi:10.1586/erv.09.59.
   PubMed Web of Science ®Google Scholar
• Li Z, Xu J, Tan H, Zhang C, Chen J, Ni L, Yun X, Huang Y, Wang W. Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. Int J Infect Dis. 2020;99:149–55. doi:10.1016/j.ijid.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Clarke E, Saidu Y, Adetifa JU, Adigweme I, Hydara MB, Bashorun AO, Moneke-Anyanwoke N, Umesi A, Roberts E, Cham PM. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in the Gambia. Lancet Glob Health. 2016;4(8):e534–47. doi:10.1016/S2214-109X(16)30075-4.
   PubMed Web of Science ®Google Scholar
• Fescharek DR, Kübler J, Elsasser U, Frank M, G??thlein, P. Medical Dictionary for Regulatory Activities (MedDRA). Int J Pharm Med. 2004;18(5):259–69. doi:10.2165/00124363-200418050-00001.
   Google Scholar
• Li L, Yang R, Cai J, Zheng J. [Evaluation of the safety of diphtheria, tetanus and acellular pertussis containing combination vaccines in Chengdu, 2015-2019]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(9):958–62. doi:10.3760/cma.j.cn112150-20200417-00593.
   PubMedGoogle Scholar
• Singleton JA. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine. 1999;17(22):2908–17. doi:10.1016/S0264-410X(99)00132-2.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33:4398–405. doi:10.1016/j.vaccine.2015.07.035.
   PubMed Web of Science ®Google Scholar